Rocket Pharmaceuticals (Rocket Pharmaceuticals) Total Payout Yield % : -9.31 (As of May. 21, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Rocket Pharmaceuticals's current Total Payout Yield % is -9.31%.

Rocket Pharmaceuticals Total Payout Yield % Historical Data

The historical data trend for Rocket Pharmaceuticals's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Total Payout Yield % Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Yield %

Get a 7-Day Free Trial

-14.29

-8.41

-2.68

-10.03

-7.70

Rocket Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Yield %	Get a 7-Day Free Trial															-5.32	-0.05	-41.03	-0.06	-0.19

Competitive Comparison of Rocket Pharmaceuticals's Total Payout Yield %

For the Biotechnology subindustry, Rocket Pharmaceuticals's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rocket Pharmaceuticals's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Total Payout Yield % falls into.

Rocket Pharmaceuticals Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Rocket Pharmaceuticals's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	208.394	+	0)	/	2705.760531
	=	-7.70%

Rocket Pharmaceuticals's annualized Total Payout Yield % for the quarter that ended in Mar. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	1.184	+	0)	*	4	/	2442.019404
	=	-0.19%

Rocket Pharmaceuticals Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Rocket Pharmaceuticals Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

9IP1:Germany

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Executives

John Militello	officer: See Remarks	C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker	director	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah	director, officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel	officer: Chief Operating Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White	officer: Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson	officer: General Counsel	C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada	officer: Chief Financial Officer	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork	director	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam	officer: SVP - Finance & PFO	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell	director, officer: See Remarks	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi	director	412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder	officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016